Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Fineline Cube May 7, 2026
Company Deals

Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto

Fineline Cube Feb 24, 2023

US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...

Company Deals

ConjuStar Peptide-Drug Conjugate Angel Financing

Fineline Cube Feb 24, 2023

Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...

Policy / Regulatory

Guangdong Adds Hospitals to GBA Drug and Device Green Channel

Fineline Cube Feb 23, 2023

The Health Commission of Guangdong Province (GDHC) has released a second list of designated medical...

Company Drug

Zai Lab to Present Zejula OS Study Results at ESMO Congress

Fineline Cube Feb 23, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...

Company Deals

Huadong Medicine Expands Global Partnership with Scohia Pharma for SCO-094

Fineline Cube Feb 23, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) and Japanese firm Scohia Pharma Inc. have announced...

Company Drug

Zai Lab’s SUL-DUR NDA Accepted for Review by NMPA

Fineline Cube Feb 23, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has revealed that a New Drug Application...

Company Deals R&D

Changchun BCHT Biotechnology and IMB CAMS Enter Five-Year Research Pact

Fineline Cube Feb 23, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a five-year scientific research cooperation...

Company Deals

Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca

Fineline Cube Feb 23, 2023

China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...

Company

Legend Biotech No Longer Faces Delisting from Nasdaq

Fineline Cube Feb 22, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released a notice stating that it is no...

Company Drug

Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA

Fineline Cube Feb 22, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...

Company Medical Device

MicroPort CardioFlow’s TAVI Product Approved in Thailand

Fineline Cube Feb 22, 2023

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has...

Company Deals

TransThera Biosciences Completes Series D+ Financing Round

Fineline Cube Feb 22, 2023

China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...

Company Drug

Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance

Fineline Cube Feb 22, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...

Company Deals

Huahai Pharma Raises Funds for Digital Manufacturing and API Platform

Fineline Cube Feb 22, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...

Company Deals R&D

Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center

Fineline Cube Feb 22, 2023

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...

Company Drug

Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing

Fineline Cube Feb 22, 2023

February 23 will mark the oral hearing phase for the patent challenge case brought by...

Company Drug

Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment

Fineline Cube Feb 22, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...

Company Drug

Sinovac’s Hepatitis A Vaccine Healive Approved in Egypt

Fineline Cube Feb 22, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced obtaining market approval from the Egyptian Drug...

Company Medical Device

Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval

Fineline Cube Feb 22, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...

Company Deals

Merck KGaA Partners with Beijing for Drug Imports via Beijing Ports

Fineline Cube Feb 22, 2023

Merck KGaA (ETR: MRK), a leading German pharmaceutical company, has struck a partnership with the...

Posts pagination

1 … 554 555 556 … 661

Recent updates

  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
  • Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion
  • Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.